CTOs on the Move

Garuda Therapeutics

www.garudatx.com

 
Garuda Therapeutics seeks to create a world which eliminates the dependency on donor or patient cells for blood stem cell transplants. Our platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible transgene-free blood stem cell therapies. Like bone marrow transplants, our technology could provide potentially curative therapies for more than 70 diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.garudatx.com
  • 215 First Street Suites 340-350
    Cambridge, MA USA 02142
  • Phone: 559.594.4380

Executives

Name Title Contact Details
David DiGiusto
Chief Technology Officer Profile

Similar Companies

Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people`s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world`s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Ecomark

Ecomark Ltd is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Id Labs Inc

Id Labs Inc is a London, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Canary Medical

Canary Medical was conceived and created by a team of surgeons, medical device developers, and IoT experts with the vision that (1) healthcare transformation requires better and cheaper healthcare data, (2) better monitoring and better data will produce better outcomes at lower costs, and (3) the patient`s own their healthcare data and should be compensated for its use.

OncoResponse

OncoResponse Inc., a privately held immuno-oncology company, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to the discovery of cancer therapeutics.